Huachansu suppresses human bladder cancer cell growth through the Fas/Fasl and TNF-α/TNFR1 pathway in vitro and in vivo

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Yang, Tao ^a   Shi, Runlin ^a   Chang, Lei ^b   Tang, Kun ^a   Chen, Ke ^a   Yu, Gan ^a   Tian, Yuanfeng ^a   Guo, Yonglian ^b   He, Wei ^a   Song, Xiaodong ^a   Xu, Hua ^a   Ye, Zhangqun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

Apoptosis; Bladder cancer; Fas Fasl; Huachansu; TNF alpha TNFR1

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; FAS ANTIGEN; FAS LIGAND; HUACHANSU; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; AMPHIBIAN VENOM; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BLADDER TUMOR; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

AMPHIBIAN VENOMS; ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; HETEROGRAFTS; HUMANS; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 84925016654     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0134-9     Document Type: Article

References (31)

1. Bryan RT. Bladder cancer and cancer stem cells: basic science and implications for therapy. Sci World J. 2011;11:1187-94.
2. Arentsen HC, Hendricksen K, Oosterwijk E, Witjes JA. Experimental rat bladder urothelial cell carcinoma models. World J Urol. 2009;27:313-7.
3. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL. Intravesical treatments of bladder cancer: review. Pharm Res. 2008;25:1500-10.
4. Schenk-Braat EA, Bangma CH. Immunotherapy for superficial bladder cancer. Cancer Immunol Immun CII. 2005;54:414-23.
5. Gartrell BA, Sonpavde G. Emerging drugs for urothelial carcinoma. Expert Opin Emerging Drugs. 2013;18:477-94.
6. Orang-Ojong BB, Munyangaju JE, Wei MS, Lin M, Wei FG, Foukunang C, et al. Impact of natural resources and research on cancer treatment and prevention: A perspective from Cameroon. Mol Clin Oncol. 2013;1:610-20.
7. Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, et al. Cancer wars: natural products strike back. Frontiers Chem. 2014;2:20.
8. Qi F, Li A, Inagaki Y, Kokudo N, Tamura S, Nakata M, et al. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol. 2011;11:342-9.
9. Qi F, Inagaki Y, Gao B, Cui X, Xu H, Kokudo N, et al. Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Sci. 2011;102:951-8.
10. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, et al. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 2009;115:5309-18.
11. Ye M, Guo H, Guo H, Han J, Guo D. Simultaneous determination of cytotoxic bufadienolides in the Chinese medicine ChanSu by high-performance liquid chromatography coupled with photodiode array and mass spectrometry detections. J Chromatogr B Anal Technol Biomed Life Sci. 2006;838:86-95.
12. Watabe M, Ito K, Masuda Y, Nakajo S, Nakaya K. Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene. 1998;16:779-87.
13. Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng Y, et al. PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anti-Cancer Drugs. 2009;20:59-64.
14. Yu CH, Kan SF, Pu HF, Jea Chien E, Wang PS. Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci. 2008;99:2467-76.
15. Reis LO, Ferreira U, Billis A, Cagnon VH, Favaro WJ. Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guerin immunotherapy for nonmuscle invasive bladder cancer. J Urol. 2012;187:438-45.
16. To KK, Au-Yeung SC, Ho YP. Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine-platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles. Anti-Cancer Drugs. 2006;17:673-83.
17. Mehta RG, Murillo G, Naithani R, Peng X. Cancer chemoprevention by natural products: how far have we come? Pharm Res. 2010;27:950-61.
18. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 1999;6:1028-42.
19. Burkle A, Brabeck C, Diefenbach J, Beneke S. The emerging role of poly(ADP-ribose) polymerase-1 in longevity. Int J Biochem Cell Biol. 2005;37:1043-53.
20. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A. 2006;103:18314-9.
21. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis Int J Program Cell Death. 2007;12:1543-68.
22. Heath-Engel HM, Chang NC, Shore GC. The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family. Oncogene. 2008;27:6419-33.
23. Huang X, Lu Z, Lv Z, Yu T, Yang P, Shen Y, et al. The Fas/Fas ligand death receptor pathway contributes to phenylalanine-induced apoptosis in cortical neurons. PLoS ONE. 2013;8:e71553.
24. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-30.
25. Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S, Konishi N. c-Jun NH2-terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells. Prostate. 2003;55:265-80.
26. Lavrik IN, Krammer PH. Regulation of CD95/Fas signaling at the DISC. Cell Death Differ. 2012;19:36-41.
27. Kober AM, Legewie S, Pforr C, Fricker N, Eils R, Krammer PH, et al. Caspase-8 activity has an essential role in CD95/Fas-mediated MAPK activation. Cell Death Dis. 2011;2:e212.
28. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745-56.
29. Bhardwaj A, Aggarwal BB. Receptor-mediated choreography of life and death. J Clin Immunol. 2003;23:317-32.
30. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181-90.
31. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996;274:782-4.